Afficher la couverture 'Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation. Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation: Single-domain antibodies against protease nexin-1 | Kawecki, Charlotte' en grand format
/5

0 avis

Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation. Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation: Single-domain antibodies against protease nexin-1

Archive ouverte

Kawecki, Charlotte | Aymonnier, Karen | Ferrière, Stephen | Venisse, Laurence | Arocas, Véronique | Boulaftali, Yacine | Christophe, Olivier, D | Lenting, Peter, J. | Bouton, Marie-Christine | Denis, Cécile, V

Edité par CCSD ; Wiley -

International audience. Background: Protease nexin-1 (PN-1) is a member of the serine protease inhibitor (Serpin)-family, with thrombin as its main target. Current polyclonal and monoclonal antibodies against PN-1 frequently cross-react with Plasminogen activator inhibitor-1 (PAI-1), a structurally and functionally homologous Serpin. Objectives: Here, we aimed to develop inhibitory single-domain antibodies (VHHs) that show specific binding to both human (hPN-1) and murine (mPN-1) PN-1. Methods: PN-1-binding VHHs were isolated via phage-display using llama-derived or synthetic VHH-libraries. Following bacterial expression, purified VHHs were analyzed in binding and activity assays.Results and Conclusions: By using a llama-derived library, 2 PN-1 specific VHHs were obtained (KB-PN1-01 & KB-PN1-02). Despite their specificity, none displayed inhibitory activity towards hPN-1 or mPN-1. From the synthetic library, 4 VHHs (H12, B11, F06, A08) could be isolated that combined efficient binding to both hPN-1 and mPN-1 with negligible binding to PAI-1. Of these, B11, F06 and A08 were able to fully restore thrombin activity by blocking PN-1. As monovalent VHH, IC50-values for hPN-1 were 50±10 nM, 290±30 and 960±390 nM, for B11, F06 and A08, respectively, and 1580±240 nM, 560±130 nM and 2880±770 nM for mPN-1. The inhibitory potential was improved 4- to 7-fold when bivalent VHHs were engineered. Importantly, all VHHs could block PN-1 activity in plasma as well as PN-1 released from activated platelets, one of the main sources of PN-1 during hemostasis.In conclusion, we report the generation of inhibitory anti-PN-1 antibodies using a specific approach to avoid cross-reactivity with the homologous Serpin PAI-1.

Suggestions

Du même auteur

Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia

Archive ouverte | Aymonnier, Karen | CCSD

International audience. Hemophilia A and B, diseases caused by the lack of factor VIII (FVIII) and factor IX (FIX) respectively, lead to insufficient thrombin production, and therefore to bleeding. New therapeutic s...

Development of single domain antibodies targeting protease nexin-1 as a strategy for hemophilia treatment

Archive ouverte | Kawecki, Charlotte | CCSD

International audience

Hematopoietic protease nexin-1 protects against lung injury by preventing thrombin signaling in mice

Archive ouverte | François, Deborah | CCSD

International audience. Coagulation and fibrinolytic system deregulation has been implicated in the development of idiopathic pulmonary fibrosis, a devastating form of interstitial lung disease. We used intratrachea...

Chargement des enrichissements...